Lucid Diagnostics (Lucid Diagnostics) Gross Margin % : -40.10% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Lucid Diagnostics's Gross Profit for the three months ended in Dec. 2023 was $-0.42 Mil. Lucid Diagnostics's Revenue for the three months ended in Dec. 2023 was $1.04 Mil. Therefore, Lucid Diagnostics's Gross Margin % for the quarter that ended in Dec. 2023 was -40.10%.

The historical rank and industry rank for Lucid Diagnostics's Gross Margin % or its related term are showing as below:

LUCD' s Gross Margin % Range Over the Past 10 Years
Min: -858.62 Med: -146.25 Max: -17
Current: -146.21

During the past 5 years, the highest Gross Margin % of Lucid Diagnostics was -17.00%. The lowest was -858.62%. And the median was -146.25%.

LUCD's Gross Margin % is ranked worse than
97.74% of 795 companies
in the Medical Devices & Instruments industry
Industry Median: 53.37 vs LUCD: -146.21

Lucid Diagnostics had a gross margin of -40.10% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Lucid Diagnostics was 0.00% per year.

Lucid Diagnostics Gross Margin % Historical Data

The historical data trend for Lucid Diagnostics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucid Diagnostics Gross Margin % Chart

Lucid Diagnostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

-17.00

-858.62

-146.25

Lucid Diagnostics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial											-1,344.64	-200.00	-874.21	-108.68	-40.10

Competitive Comparison of Lucid Diagnostics's Gross Margin %

For the Medical Devices subindustry, Lucid Diagnostics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucid Diagnostics's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's Gross Margin % falls into.

Lucid Diagnostics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Lucid Diagnostics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-3.6	/	2.428
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(2.428 - 5.979)	/	2.428
	=	-146.25 %

Lucid Diagnostics's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.4	/	1.04
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(1.04 - 1.457)	/	1.04
	=	-40.10 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Lucid Diagnostics (NAS:LUCD) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Lucid Diagnostics had a gross margin of -40.10% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Lucid Diagnostics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Lucid Diagnostics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucid Diagnostics (Lucid Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Madison Avenue, 25th Floor, New York, NY, USA, 10017

Website

https://www.luciddx.com

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Executives

Stanley Lapidus	director	101 HARTWELL AVE., LEXINGTON MA 02421
Debra White	director	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon	officer: General Counsel	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil	officer: Chief Operating Officer	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc.	10 percent owner	360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog	director, officer: Chief Executive Officer	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath	officer: Chief Financial Officer	C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw	director	150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov	director
David F Wurtman	officer: Chief Medical Officer	ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165